Ziopharm Oncology Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 07, 2020 16:05 ET
|
ZIOPHARM Oncology Inc
– Regulatory discussions with FDA advance Ziopharm TCR-T IND process –– Enrollment on track in Controlled IL-12 phase 2 clinical trial with Regeneron’s Libtayo®;Controlled IL-12 clinical data update...
Ziopharm Oncology Announces Poster Presentations at the 2020 American Society of Clinical Oncology Virtual Meeting
April 30, 2020 08:00 ET
|
ZIOPHARM Oncology Inc
BOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that it will be presenting data from its Controlled IL-12 program, or Ad-RTS-hIL-12 plus veledimex...
Ziopharm Oncology to Report First Quarter 2020 Financial Results and Host a Conference Call and Webcast on May 7, 2020
April 27, 2020 08:30 ET
|
ZIOPHARM Oncology Inc
BOSTON, April 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, May 7, at 4:30 pm EDT to provide a...
Ziopharm Oncology Reports Financial Results for Fourth Quarter and Full Year 2019
March 02, 2020 16:05 ET
|
ZIOPHARM Oncology Inc
– Emergence of TCR program, Controlled IL-12 data, strengthened team highlight 2019 – – Balance sheet strengthened; cash of approximately $177 million funds operations to mid-2022 – – Clinical trial...
Ziopharm Oncology Presentation at the Barclays Global Healthcare Conference to be Webcast
February 28, 2020 08:30 ET
|
ZIOPHARM Oncology Inc
BOSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a...
Ziopharm Oncology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Results on March 2, 2020
February 24, 2020 08:30 ET
|
ZIOPHARM Oncology Inc
BOSTON, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, March 2, at 4:30 p.m. ET to...
Ziopharm Oncology Announces Pricing of Public Offering of Common Stock
February 05, 2020 09:02 ET
|
ZIOPHARM Oncology Inc
BOSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced the pricing of an underwritten public offering of 27,826,086 shares of its common stock at a public...
Ziopharm Oncology Announces Proposed Public Offering of Common Stock
February 04, 2020 16:01 ET
|
ZIOPHARM Oncology Inc
BOSTON, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that it intends to offer and sell shares of its common stock in an underwritten registered public...
Ziopharm Oncology Announces Recent Publications in Peer-Reviewed Scientific Journals
January 30, 2020 08:45 ET
|
ZIOPHARM Oncology Inc
– Encouraging long-term outcome data after infusion of Sleeping Beauty-modified CAR-T published in Blood – – TCRs targeting mutations in TP53 obtained from T cells in peripheral blood to overcome...
Ziopharm Oncology Presentation at the 38th Annual J.P. Morgan Healthcare Conference to be Webcast
December 19, 2019 08:45 ET
|
ZIOPHARM Oncology Inc
BOSTON, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a...